Assessment of the Effectiveness of Ich Tam Khang as a Supportive Therapy for Chronic Heart Failure

Authors

  • Bien D. Vu Cardiovascular Institute, 108 Central Military Hospital, Hanoi, Vietnam
  • Son N. Pham Cardiovascular Institute, 108 Central Military Hospital, Hanoi, Vietnam
  • Thanh D. Le Cardiovascular Institute, 108 Central Military Hospital, Hanoi, Vietnam
  • Ly K. Nguyen Cardiovascular Institute, 108 Central Military Hospital, Hanoi, Vietnam
  • Dang H. Luong Cardiovascular Institute, 108 Central Military Hospital, Hanoi, Vietnam
  • Quynh Luu Cardiovascular Institute, 108 Central Military Hospital, Hanoi, Vietnam
  • Duc V. Dang Cardiovascular Institute, 108 Central Military Hospital, Hanoi, Vietnam
  • Ba X. Hoang Allergy Research Group, Alameda, California, USA

DOI:

https://doi.org/10.6000/1929-5634.2014.03.03.2

Keywords:

Ich Tam Khang, heart failure, herbal medicine, nutritional supplement.

Abstract

Background: Heart failure is a chronic disease needing lifelong management. Despite the advances that have been made in the treatment of the disease, both the longevity and quality of life for those with chronic heart failure remain impaired. A more effective therapeutic approach with less negative side effects is still needed. In this study, we evaluate Ich Tam Khang (ITK), the poly-ingredient herbal and nutritional preparation with multiple physiological actions, as a supportive therapy for patients with chronic heart failure.

Aims of Study: To evaluate the effectiveness and safety of Ich Tam Khang as an adjunctive treatment of chronic heart failure.

Methods: A total of 60 patients with chronic congestive heart failure were enrolled in this open label, cross-sectional and prospective study. All patients were treated with a conventional regimen (digoxin, diuretics, angiotensin-converting-enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), beta blockers) for at least 4 weeks before being divided into two equal groups. In the treated patients with ITK, patients received conventional therapy plus 4 tablets ITK per day added in two divided doses. In the control patients, all patients kept the same conventional regimen without ITK. All patients were followed up for 3 months for clinical and para-clinical outcomes.

Result: The symptoms of heart failure (dyspnea, palpitation, peripheral edema, neck vein distention, heptojugular reflex) decreased. Heart rate and blood pressure stabilized during treatment in the treated patients with ITK. Additionally, total cholesterol and HDL-cholesterol normalized in the patients treated with ITK. Most of echocardiography parameters in the ITK treated patients were superior to the control patients. ITK is safe and it has no side effects.

Conclusion: ITK as a combination of herbal and nutritional preparation is effective in reducing heart failure symptoms, improving patient’s quality of life for the patients with decompensated heart failure and reducing total cholesterol and LDL-C.

References

Clark AP, McDougall G, Riegel B, Joiner-Rogers G, Innerarity S, Meraviglia M, et al. Health Status and Self-care Outcomes After an Education-Support Intervention for People With Chronic Heart Failure. J Cardiovasc Nurs 2014. http://dx.doi.org/10.1097/JCN.0000000000000169 DOI: https://doi.org/10.1097/JCN.0000000000000169

Liu X, Yu H, Pei J, Chu J, Pu J, Zhang S. Clinical Characteristics and Long-term Prognosis in Patients with Chronic Heart Failure and Reduced Ejection Fraction in China. Heart Lung Circ 2014; S1443-9506(1414)00159-00150 [pii] DOI: 00110.01016/j.hlc.02014.00102.00022

Wang J, Xiong X, Feng B. Cardiovascular effects of salvianolic Acid B. Evid Based Complement Alternat Med 2013; 2013: 247948. DOI: https://doi.org/10.1155/2013/247948

Lu Y, Zheng Y, Liu X, Liang X, Ngai S, Li T, Zhang W. Metabolomic profiles of myocardial ischemia under treatment with salvianolic acid B. Chin Med 2012; 7: 6. http://dx.doi.org/10.1186/1749-8546-7-6 DOI: https://doi.org/10.1186/1749-8546-7-6

Jang JY, Kim TS, Cai J, Kim J, Kim Y, Shin K, et al. Nattokinase improves blood flow by inhibiting platelet aggregation and thrombus formation. Lab Anim Res 2013; 29: 221-225. http://dx.doi.org/10.5625/lar.2013.29.4.221 DOI: https://doi.org/10.5625/lar.2013.29.4.221

Park KJ, Kang JI, Kim TS, Yeo IH. The antithrombotic and fibrinolytic effect of natto in hypercholesterolemia rats. Prev Nutr Food Sci 2012; 17: 78-82. http://dx.doi.org/10.3746/pnf.2012.17.1.078 DOI: https://doi.org/10.3746/pnf.2012.17.1.078

Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann N Y Acad Sci 2004; 1033: 79-91. http://dx.doi.org/10.1196/annals.1320.007 DOI: https://doi.org/10.1196/annals.1320.007

Hiatt WR. Carnitine and peripheral arterial disease. Ann N Y Acad Sci 2004; 1033: 92-98. http://dx.doi.org/10.1196/annals.1320.008 DOI: https://doi.org/10.1196/annals.1320.008

Iliceto S, Scrutinio D, Bruzzi P, D'Ambrosio G, Boni L, Di Biase M, et al. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol 1995; 26: 380-387. http://dx.doi.org/10.1016/0735-1097(95)80010-E DOI: https://doi.org/10.1016/0735-1097(95)80010-E

Lau CW, Yao XQ, Chen ZY, Ko WH, Huang Y. Cardiovascular actions of berberine. Cardiovasc Drug Rev 2001; 19: 234-244. http://dx.doi.org/10.1111/j.1527-3466.2001.tb00068.x DOI: https://doi.org/10.1111/j.1527-3466.2001.tb00068.x

Marin-Neto JA, Maciel BC, Secches AL, Gallo Junior L. Cardiovascular effects of berberine in patients with severe congestive heart failure. Clin Cardiol 1988; 11: 253-260. http://dx.doi.org/10.1002/clc.4960110411 DOI: https://doi.org/10.1002/clc.4960110411

Zeng XH, Zeng XJ, Li YY. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2003; 92: 173-176. http://dx.doi.org/10.1016/S0002-9149(03)00533-2 DOI: https://doi.org/10.1016/S0002-9149(03)00533-2

Costanzo MR, Mills RM, Wynne J. Characteristics of "Stage D" heart failure: insights from the Acute Decompensated Heart Failure National Registry Longitudinal Module (ADHERE LM). Am Heart J 2008; 155: 339-347. http://dx.doi.org/10.1016/j.ahj.2007.10.020 DOI: https://doi.org/10.1016/j.ahj.2007.10.020

Adler ED, Goldfinger JZ, Kalman J, Park ME, Meier DE. Palliative care in the treatment of advanced heart failure. Circulation 2009; 120: 2597-2606. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.869123 DOI: https://doi.org/10.1161/CIRCULATIONAHA.109.869123

Downloads

Published

2014-10-03

How to Cite

Vu, B. D., Pham, S. N., Le, T. D., Nguyen, L. K., Luong, D. H., Luu, Q., Dang, D. V., & Hoang, B. X. (2014). Assessment of the Effectiveness of Ich Tam Khang as a Supportive Therapy for Chronic Heart Failure. Journal of Nutritional Therapeutics, 3(3), 116–121. https://doi.org/10.6000/1929-5634.2014.03.03.2

Issue

Section

Articles